One of the largest meta-study of cancer survival rates ever done has been published in the journal, “The Lancet”. Global surveillance of cancer survival 1995—2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries
The study highlights the massive discrepancy in survival rates between some countries. Cervical cancer, for example, has a 70% 5 year survival rate in some countries, but 40% in others. Some forms of leukemia offer 90%+ survival rates in the United States, but 16% in some parts of the Middle East.
The study used 279 population based cancer registries, from 67 countries to gather data. That encompassed more than 25.7 million adults and 75,000 children. The types of cancers involved were cancer of the stomach, colon, liver, rectum, lung, breast, cervix, ovary and prostate. They also examined childhood leukemia.
The study found that 5 year survival rates for common cancers like colorectal and breast has been increasing in developed countries. Developing countries were lagging behind.
It also found that liver and lung cancers remain extremely dangerous, with very low survival rates around the world. 20% for all of Europe, 15-19% in North America and as low as 7-9% in parts of asia.
Some of the good news included a 10-20% increase in the survival rate for prostate cancers. At it’s lowest, the survival rate is 60% in Thailand and Bulgaria, 95% at its highest in Brazil, Puerto Rico, and the USA.
For cervical cancer, 5-year survival rates range from less than 50% to more than 70%. Regional variations are much wider, and improvements between 1995—99 and 2005—09 have generally been small.